For years, MOTS-c has primarily been discussed in the context of metabolism, exercise, insulin sensitivity, cellular stress, and mitochondrial signaling. A new study published in eLife on August 18, 2026, adds a completely different dimension to the story. Researchers report evidence that MOTS-c may function as a mitochondrial-encoded host-defense peptide, with direct antibacterial activity and immunomodulatory effects. The finding raises an intriguing question: Could mitochondria do more than regulate cellular energy? Could they also participate directly in immune defense? What Is MOTS-c? MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. Unlike many signaling peptides encoded by nuclear DNA, MOTS-c is encoded within the human mitochondrial genome. It has attracted significant research interest because of its reported involvement in metabolic regulation, cellular stress responses, and mitochondrial signaling. The new eLife research suggests that its biological role may extend into another fundamental area: host defense. MOTS-c Showed Direct Antibacterial Activity The researchers first investigated whether MOTS-c could interact directly with bacteria. Their experiments included Escherichia coli and methicillin-resistant Staphylococcus aureus (MRSA). The researchers found that MOTS-c interacted with bacterial cells and promoted bacterial aggregation. They also identified structural features of MOTS-c that appear important for this activity, including hydrophobic and positively charged regions. The proposed mechanism is consistent with how other host-defense peptides can interact with bacterial membranes. In other words, MOTS-c wasn't simply being studied as a metabolic signaling molecule. Researchers were observing behavior associated with antimicrobial peptides. Then Researchers Took the Study Into Mice The next question was whether these antibacterial effects could translate into an animal model. Researchers used an acute peritonitis model involving MRSA in mice.

Feeling flat. Foggy. Running on empty. Those descriptions have become common in conversations about energy and cognitive performance. And they have also helped push nicotinamide mononucleotide (NMN) into the spotlight. But the interesting question isn't whether NMN is a new “energy booster.” It is much more fundamental: Can increasing NAD⁺ availability change how cells manage energy? The answer from current research is increasingly interesting—but considerably more nuanced than the claims circulating online. NMN Isn't a Stimulant NMN is a naturally occurring nucleotide and an intermediate in the biosynthesis of nicotinamide adenine dinucleotide (NAD⁺). NAD⁺ is one of the most important metabolic cofactors in biology. It participates in: - Glycolysis - The citric acid cycle - Oxidative phosphorylation - Redox reactions - DNA repair - Sirtuin activity - Cellular stress responses In simple terms, NAD⁺ helps cells transfer energy through the biochemical reactions that ultimately support ATP production. That makes NMN interesting for mitochondrial research. But it also explains why describing NMN as a stimulant is misleading. A stimulant primarily changes neural or hormonal signaling. NMN is being investigated for something much more fundamental: NAD⁺ metabolism. The NAD⁺ Connection Think of cellular energy production as a network rather than a single switch. Nutrients provide the raw materials. Metabolic pathways extract electrons from those nutrients. NAD⁺ accepts and transfers those electrons. The electron transport chain then uses the resulting reducing equivalents to establish the proton gradient that drives ATP synthesis. So NAD⁺ isn't ATP. And NMN isn't ATP either. Instead, NMN sits upstream in a pathway that can contribute to maintaining the NAD⁺ pool. That distinction matters. The scientific question is not: “Does NMN directly give the cell energy?” It's: “Does increasing NAD⁺ availability alter the metabolic environment in which cells produce and use energy?”

Eli Lilly's strategy may be becoming much bigger than simply developing and selling medicines. The pharmaceutical industry has traditionally operated in relatively defined lanes. Drugmakers discover molecules. Doctors prescribe them. Pharmacies dispense them. Insurers determine much of the payment structure. But those boundaries are becoming increasingly blurred. Eli Lilly is an especially interesting company to watch because its recent moves touch several different parts of the healthcare ecosystem: drug discovery, direct-to-patient access, digital health, and biometric data. Individually, these developments aren't necessarily revolutionary. Put them together, however, and a much larger strategic picture starts to emerge. The Four Layers of Healthcare A useful way to understand the modern healthcare ecosystem is to divide it into four layers. 1. The Molecule Who develops the medicine? 2. The Channel Who gets that medicine to the patient? 3. The Data Who knows what happens to the patient after treatment? 4. The Interpretation Who turns all of that information into recommendations? Historically, no single pharmaceutical company controlled all four. That may be changing. Layer One: Owning the Molecule Lilly remains a traditional pharmaceutical powerhouse because it develops its own medicines. Zepbound and other Lilly products are examples of the company's conventional drug-development model. But Lilly also recognized early that artificial intelligence could fundamentally change how medicines are discovered. In January 2024, Lilly entered a strategic research collaboration with Isomorphic Labs, the Alphabet-backed AI drug-discovery company. The agreement included a $45 million upfront payment and potential milestone payments of up to $1.7 billion, excluding royalties. The goal was to use AI-driven approaches to discover small-molecule therapeutics against multiple targets. That is significant because it represents something bigger than simply outsourcing research.